Low level determination of 4-amino-2-ethoxy-cinnamic acid and its ethyl ester in a drug substance and its formulation prototypes by HPLC-UV-DAD

Journal of Chromatographic Science

Volumn 47, Issue 4, 2009, Pages 315-319

  Soman, A ^a   Jacob, S ^a   Swanek, F ^a  

^a BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 65949092783     PISSN: 00219665     EISSN: None     Source Type: Journal    
DOI: 10.1093/chromsci/47.4.315     Document Type: Article

References (15)

1. K. Echhardt, M.T. King, E. Gocke, and D. Wild. Mutagenicity study of Remsen-Fahlberg saccharin and contaminants. Toxicol. Lett. 7: 51-60 (1980).
2. R.M. Riggin, W.I. Margard, and G.W. Kinzer. Characterization of impurities in commercial lots of sodium saccharin produced by Sherwin-Wiiliams process II, Mutage. Food Chem Toxicol. 21: 11-17 (1983).
3. A.G. Butterfield, N.M. Curran, E.G. Lovering, F.F. Matsui, D.L. Robertson, and R.W. Sears. Determination of hydrazine in Pharmaceuticals I. Isoniazid. Can.J. Pharm. Sci. 16(1): 15-19 (1981).
4. F. Matsui, D.S. Robertson and E.G. Lovering. Determination of hydrazine in pharmaceuticals III: hydralazine and isoniazid using GLC. J. Pharm. Sci. 72: 948-51 (1983).
5. O. Friscia, R. Pulci, F. Fassio, and R. Comelli. Chemical reagents as potential impurities of pharmaceutical products: investigations on their genotoxic activity. J. Environ. Pathol. Toxicol. Oncol. 13: 89-110 (1994).
6. M.L. Kropko, J.C. Jaen, J.C. Theiss, S. Wold, B.W. Caprathe, and L.D. Wise. Chemical purity and mutagenicity: case study of a drug in development. Mutat. Res. 281 (4): 233-38 (1992).
7. J.P. Boehlert. Impurities - Where are we now? Pharm. Technol. 21: 56-60 (1997).
8. European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), June 2004. Guideline on the Limits of Genotoxic Impurities (draft).
9. L. Miller, R.J. Mauthe, CM. Riley, et al. A rationale for determining, testing, and controlling specific impurities in pharmaceuticals that possess potential for genotoxicity. Reg. Toxicol. Pharmacol. 44: 198-211 (2006).
10. L. Muller and P. Kasper. Human biological relevance and the use of threshold arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutat. Res. 464: 19-34 (2000).
11. J. Ashby and R.W. Tennant. Definitive relationships among chemical structure, carcinogenicity and mutagenicity for 301 chemicalstested by the U.S. NTP. Mutat. Res. 257 229-306 (1991).
12. R. Harkov, S.J. Gianti, J.W. Bozzelli, J.E. LaRegina. Monitoring volatile organic compounds at hazardous and sanitary landfills in New Jersey. J. Environ Sci. Health A 20: 491-501 (1985).
13. Y.C. Fiamegos, C.G. Nanos, J. Vervoort, and C.D. Stalikas. Analytical procedure for the in-vial derivatization-extraction of phenolic acids and flavanoids in methanol and aqueous plant extracts followed by gas chromatography with mass-selective detection. J. Chromatogr. 1041: 11-18 (2004).
14. J. Krzek, J. Kaleta, U. Hubicka, and A. Niedzwiedz. Reversed-phase high-performance liquid chromatographic determination of selected phenolic acids in propolis concentrates in terms of standardization for drug manufacturing purposes. J. AOAC Inter. 89: 352-58 (2006).
15. M.J. Arin, M.T. Diez, and J.A. Resines. High-performance liquid chromatographic determination of phenolic acids isolated from plants. J. Liq. Chrom. 18: 4183-92 (1995).